Founded in 1996, China Pioneer Pharma Holdings Limited (the "Company") is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China. We constantly introduce products embedded with technologies that represent international advanced level into Chinese market and benefit to Chinese patients. On 5 November 2013, the Company was successfully listed on the main board of the Stock Exchange of Hong Kong Limited with stock code HK.01345.

As a international company with global vision, the Company has established long-term and stable as well as mutual beneficial cooperation with a number of renowned international suppliers. The network of overseas suppliers lays the foundation of the sustainable development of the Company through comprehensive and effective product introduction and supplier cooperation. The Company has built up a sales system covering whole China. With long-term efforts, the Company has created a unique brand foundation.

Currently, the Company has established long-term stable cooperative relationship with Alcon of USA, Alfasigma of Italy, Aenova of Germany, Polichem of Switzerland, Fleet of USA, Ivoclar Vivadent of Principality of Liechtenstein (Wieland of Germany), NovaBay of USA.

The Company has a portfolio of pharmaceutical products, covering ophthalmology, pain management, cardiovascular, gastroenterology, immunology, gynecology and other therapeutic areas, and medical devices covering several medical specialties, including ophthalmology, orthopedics, odontology and wound care. At the same time, the Company endeavors to uplift the market value of these brands.

Based on the strong marketing and promotion team, the Company has built up a national sales system in China, and has established stable cooperative relationship with over 500 nation-wide distributors. The nation-wide network of the Company covered tens of thousands  hospitals, medical institutions and pharmacies across China.

In addition, the company is dedicated to gradually implement globalization strategy, and has begun to carry out strategic investment in overseas suppliers and innovative research and development companies. For instance, the Company has purchased equities in NovaBay, a US-based biopharmaceutical company, Paragon, a Australia-based medical device company and Worldpathol, a Spain-based animal vaccine research and development company. Through the investments, the Company is not only deepening the cooperation with overseas suppliers, but also gradually realizing the goal of internationalization.

Looking forward, with rapid development of China's pharmaceutical industry, through an open-minded attitude, prospective new product introduction capability, accurate product marketing strategy, comprehensive marketing network and effective management system, the Company will seize the opportunity, take roots in the market, and realize the long term sustainable development.